RecruitingAdvanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast Cancer

Study of AVZO-021 in Patients With Advanced Solid Tumors

Eligible age

18+ yrs

Accepts

All genders

Locations

9 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).

Sponsor: Avenzo Therapeutics, Inc.